Starbucks, Gilead And Ambev Are At 52-Week Lows: Should You Buy The Dip?
Portfolio Pulse from Surbhi Jain
Starbucks, Gilead Sciences, and Ambev have hit their 52-week lows, presenting potential buy-the-dip opportunities. Starbucks trades around $86.83 with a potential upside of 17.23%, Gilead at $69.32 with a 20.16% upside, and Ambev at $2.40 with a 32.51% upside, according to recent analyst ratings.
April 08, 2024 | 6:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ambev trades at $2.40, near its 52-week low, with analysts predicting a 32.51% upside.
Ambev's position near its 52-week low and the substantial 32.51% upside potential as per analysts, along with a high dividend yield, suggest a strong buy-the-dip case.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Gilead Sciences trades around $69.32, with a projected upside of 20.16% according to recent analyst ratings.
Gilead Sciences is near its 52-week low but has a significant upside of 20.16% as per analysts, coupled with a strong dividend yield, indicating a promising buy-the-dip opportunity.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Starbucks trades around $86.83, with analysts suggesting a potential upside of 17.23%.
Given its recent 52-week low and analyst projections for a 17.23% upside, Starbucks presents a strong buy-the-dip opportunity. The dividend yield further enhances its attractiveness.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90